Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review
Authors
Keywords
-
Journal
CEPHALALGIA
Volume 43, Issue 2, Pages 033310242211370
Publisher
SAGE Publications
Online
2023-01-31
DOI
10.1177/03331024221137091
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
- (2022) Peter Holzer et al. Frontiers in Physiology
- A real‐world, observational study of erenumab for migraine prevention in Canadian patients
- (2022) Werner J. Becker et al. HEADACHE
- Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
- (2022) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- P.020 Long-term safety and tolerability of atogepant 60mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial
- (2022) B Klein et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- A long-term open-label safety study of galcanezumab in Japanese patients with migraine
- (2021) Koichi Hirata et al. Expert Opinion On Drug Safety
- Hypertension: A new safety risk for patients treated with erenumab
- (2021) Suprat Saely et al. HEADACHE
- Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
- (2021) David Kudrow et al. BMC Neurology
- Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
- (2021) Fumihiko Sakai et al. HEADACHE
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Long-Term Efficacy and Safety of Erenumab
- (2021) Peter J. Goadsby et al. NEUROLOGY
- Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
- (2021) Uwe Reuter et al. ADVANCES IN THERAPY
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
- (2021) Messoud Ashina et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
- (2021) Uwe Reuter et al. CEPHALALGIA
- Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study
- (2021) Fumihiko Sakai et al. DRUG SAFETY
- Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
- (2021) Michel Dominique Ferrari et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura
- (2021) Messoud Ashina et al. JAMA Neurology
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
- (2020) Kristian Agmund Haanes et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- No ‘Wearing‐off Effect’ Seen in Quarterly or Monthly Dosing of Fremanezumab: Sub‐analysis of a Randomized Long‐term Study
- (2020) Andrew M. Blumenfeld et al. HEADACHE
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
- (2020) Janet H. Ford et al. QUALITY OF LIFE RESEARCH
- Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
- (2020) Richard B Lipton et al. CEPHALALGIA
- Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
- (2019) Alexander Rae-Grant NEUROLOGY
- CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
- (2019) Valentina Favoni et al. JOURNAL OF HEADACHE AND PAIN
- Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
- (2019) Messoud Ashina et al. CEPHALALGIA
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
- (2019) Messoud Ashina et al. CEPHALALGIA
- Vascular safety of erenumab for migraine prevention
- (2019) David Kudrow et al. NEUROLOGY
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Blocking CGRP in migraine patients – a review of pros and cons
- (2017) Marie Deen et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Erenumab (AMG 334) in episodic migraine
- (2017) Messoud Ashina et al. NEUROLOGY
- Systematic Review of Migraine Prophylaxis Adherence and Persistence
- (2016) Zsolt Hepp et al. JOURNAL OF MANAGED CARE PHARMACY
- Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.
- (2014) S. Saturni et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More